Haemonetics Stock Alpha and Beta Analysis
| HAE Stock | USD 88.46 2.91 3.40% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Haemonetics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Haemonetics over a specified time horizon. Remember, high Haemonetics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Haemonetics' market risk premium analysis include:
Beta 0.97 | Alpha 0.0848 | Risk 2.22 | Sharpe Ratio 0.13 | Expected Return 0.28 |
Haemonetics Quarterly Cash And Equivalents |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Haemonetics |
Haemonetics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Haemonetics market risk premium is the additional return an investor will receive from holding Haemonetics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Haemonetics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Haemonetics' performance over market.| α | 0.08 | β | 0.97 |
Haemonetics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Haemonetics' Buy-and-hold return. Our buy-and-hold chart shows how Haemonetics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Haemonetics Market Price Analysis
Market price analysis indicators help investors to evaluate how Haemonetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Haemonetics shares will generate the highest return on investment. By understating and applying Haemonetics stock market price indicators, traders can identify Haemonetics position entry and exit signals to maximize returns.
Haemonetics Return and Market Media
The median price of Haemonetics for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 75.81 with a coefficient of variation of 6.96. The daily time series for the period is distributed with a sample standard deviation of 5.41, arithmetic mean of 77.81, and mean deviation of 4.05. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of tradable shares by Anila Lingamneni of Haemonetics at 90.0 subject to Rule 16b-3 | 09/06/2024 |
2 | Acquisition by Laurie Miller of 2089 shares of Haemonetics subject to Rule 16b-3 | 09/13/2024 |
3 | Disposition of 238 shares by Laurie Miller of Haemonetics at 76.54 subject to Rule 16b-3 | 09/17/2024 |
4 | HAE vs. BSX Which Stock Is the Better Value Option | 09/27/2024 |
5 | Disposition of 320 shares by Josep Llorens of Haemonetics at 95.73 subject to Rule 16b-3 | 10/21/2024 |
6 | Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | 10/24/2024 |
7 | Acquisition by Stewart Strong of 6313 shares of Haemonetics at 95.73 subject to Rule 16b-3 | 11/01/2024 |
8 | Insulin Delivery Innovator PharmaSens Appoints Robert Gabbay, MD and James Peterson to Board of Directors | 11/06/2024 |
9 | Wellington Management Group LLP Increases Stake in Haemonetics Corp | 11/08/2024 |
10 | Haemonetics to lay off 75 in California facility closure | 11/12/2024 |
11 | Labcorp Adds New Capabilities to Global Trial Connect Stock to Gain | 11/13/2024 |
12 | T. Rowe Price Investment Management, Inc. Expands Stake in Haemonetics Corp | 11/14/2024 |
13 | HAE or BSX Which Is the Better Value Stock Right Now | 11/15/2024 |
14 | Reasons to Retain BSX Stock in Your Portfolio for Now | 11/19/2024 |
15 | BellRing Brands Inc. Soars to 52-Week High, Time to Cash Out | 11/20/2024 |
16 | ALGN Stock to Gain From CE Mark Win for Invisalign Palatal Expander | 11/21/2024 |
17 | MDT Stock Gains From FDA Approval for Its InPen App | 11/22/2024 |
About Haemonetics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Haemonetics or other stocks. Alpha measures the amount that position in Haemonetics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 0.011 | 0.00976 | Price To Sales Ratio | 3.31 | 4.27 |
Haemonetics Upcoming Company Events
As portrayed in its financial statements, the presentation of Haemonetics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Haemonetics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Haemonetics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Haemonetics. Please utilize our Beneish M Score to check the likelihood of Haemonetics' management manipulating its earnings.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 9th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Build Portfolio with Haemonetics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Haemonetics Backtesting, Haemonetics Valuation, Haemonetics Correlation, Haemonetics Hype Analysis, Haemonetics Volatility, Haemonetics History and analyze Haemonetics Performance. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Haemonetics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.